Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant
Diabetes Care · 01.08.2026 · 49 (8) · 1498-1506
DOI: 10.2337/dc26-0164 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 25.06.2026. Verfasst von Jingyi Qian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA. Hauptthemen laut MEDLINE: Receptor, Melatonin, MT2, Melatonin, Insulin. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NCRR NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Melatonin use quintupled in recent decades. The common melatonin receptor 1B gene (MTNR1B) variant increases risk of type 2 diabetes, raising concerns about melatonin’s adverse metabolic effects and highlighting the need for a genotype-based personalized approach. We aimed to comprehensively characterize the actions of melatonin on glucose homeostasis, including first- and second-phase β-cell responsivity to glucose, β-cell negative feedback by exogeneous insulin, insulin sensitivity, and whether such effects are stronger in MTNR1B G-allele risk carriers compared with noncarriers. RESEARCH DESIGN AND METHODS Twenty-one healthy participants of European ancestry were studied in a randomized, double-blind, placebo-controlled, crossover trial, including 10 MTNR1B risk carriers and 11 noncarriers. Each participant underwent a highly controlled 5-day laboratory protocol, during which they received 5 mg oral melatonin or placebo in randomized order on two nonconsecutive days. Glycemic dynamics were assessed using insulin-modified intravenous glucose tolerance tests with minimal-model analysis. RESULTS Melatonin worsened glucose tolerance and reduced early C-peptide responses in risk allele carriers (vs. placebo: 11.7% [95% CI 1.0–22.3] and −19.2% [−33.9 to −1.2], respectively; Padj < 0.05) but not in noncarriers. In carriers, impairments stemmed from a 40% (−52.4 to −24.3; Padj = 0.0003) suppression of glucose-stimulated first-phase β-cell responsivity, along with a slower insulin-induced decline in second-phase insulin secretion rate (64.3% [23.1–119.2]; Padj = 0.001). In carriers, melatonin also prevented exogenous insulin-induced hypoglycemia compared with placebo (zero vs. seven events, P = 0.001), but not in noncarriers. CONCLUSIONS These findings identify blunted β-cell responsivity to glucose and dysregulated insulin negative feedback as key mechanisms linking melatonin signaling to diabetes risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA.
- Division of Sleep Medicine, Harvard Medical School, Boston, MA.
- Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA.
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Mass General Brigham and Harvard Medical School, Boston, MA.
- Department of Physiology, University of Murcia, Murcia, Spain.
ORCID-Profile: Jingyi Qian, Frank A J L Scheer
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NCRR NIH HHS
- Harvard University
- ADA
- CTSA
- Independent Research Fund Denmark
- Brigham and Women's Hospital
Zitieren
APA
Qian, J., Stefanovski, D., Andersen, P. A. K., Vujovic, N., Kelly, L., Lepson, J., Nguyen, H., Byrne, S., Wang, W., Mandrup-Poulsen, T., Adler, G., Garaulet, M., Saxena, R., & Scheer, F. A. J. L. (2026). Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes Care, 49(8), 1498-1506. https://doi.org/10.2337/dc26-0164
Vancouver
Qian J, Stefanovski D, Andersen PAK, Vujovic N, Kelly L, Lepson J, et al. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes Care. 2026;49(8):1498-1506. doi:10.2337/dc26-0164
BibTeX
@article{Qian2026,
author = {Qian, Jingyi and Stefanovski, Darko and Andersen, Phillip A K and Vujovic, Nina and Kelly, Lauren and Lepson, Joshua and Nguyen, Hoa and Byrne, Sean and Wang, Wei and Mandrup-Poulsen, Thomas and Adler, Gail and Garaulet, Marta and Saxena, Richa and Scheer, Frank A J L},
title = {Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant},
journal = {Diabetes Care},
year = {2026},
volume = {49},
number = {8},
pages = {1498--1506},
doi = {10.2337/dc26-0164}
}
EUVIMED